Veeva Systems (VEEV) Investor Day 2024 summary
Event summary combining transcript, slides, and related documents.
Investor Day 2024 summary
15 Jan, 2026Strategic Vision and Long-term Goals
Announced a 2030 revenue goal of $6 billion, aiming to double revenue from 2025 to 2030, primarily through organic growth in life sciences and existing products.
Plans to expand into horizontal enterprise applications, targeting a $100B+ market opportunity, while building a next-generation application platform with a small, autonomous team.
Maintains core values of customer and employee success, product excellence, adaptability, and a strong company culture as a public benefit corporation.
Capital allocation prioritizes investment in new markets and organic growth, with flexibility for strategic acquisitions in new markets but not in core life sciences.
No material revenue contribution from new markets is expected by 2030; focus remains on execution in life sciences.
Product Strategy and Innovation
Multi-product operating model enables leadership across diverse product areas, with dedicated, lean teams for each product.
Vault Platform is central, supporting both R&D and commercial applications, and is being enhanced with innovations like Direct Data API and AI capabilities.
Migration from Veeva CRM to Vault CRM is progressing, with over 30 customers live and top 20 migrations expected to accelerate in 2025-2026.
Ongoing innovation includes new products in clinical and commercial clouds, with future launches planned.
AI strategy includes application-specific bots, direct data APIs, and a partner program to accelerate data-driven processes.
Market Opportunity and Customer Perspective
Life sciences industry TAM exceeds $20B, with penetration at ~14% and a 6%+ CAGR.
Industry is still early in digital transformation, with significant opportunity to improve automation and data integration.
Customers value quality, vision, and holistic platforms that break down silos, with large pharma and CROs as key segments.
Average products per customer continue to rise in both R&D and commercial segments.
External factors like elections and macroeconomic shifts have not materially impacted demand or customer investment cycles.
Latest events from Veeva Systems
- FY 2026 revenue and net income rose sharply, with robust outlook and accelerating AI-driven growth.VEEV
Q4 20265 Mar 2026 - All proposals were recommended for approval, with voting results to be filed publicly.VEEV
AGM 20243 Feb 2026 - Growth accelerates as unified platform, AI, and new products expand market share and customer value.VEEV
Baird 2024 Global Consumer, Technology & Services Conference1 Feb 2026 - Integrated platform and data innovation fuel durable growth and leadership in life sciences.VEEV
The 44th Annual William Blair Growth Stock Conference1 Feb 2026 - Q2 revenue up 15% year-over-year, with strong margins and raised FY2025 guidance.VEEV
Q2 202523 Jan 2026 - Vault CRM and unified platforms drive growth as life sciences invests in innovation.VEEV
Citi's 2024 Global TMT Conference22 Jan 2026 - AI-driven life sciences cloud growth targets $6B revenue and diversified leadership by 2030.VEEV
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Q3 revenue up 13% to $699M, 43.5% margin, strong subscription and AI-driven growth.VEEV
Q3 202511 Jan 2026 - Integrated innovation and disciplined growth drive confidence in $6B revenue targets by 2030.VEEV
Raymond James 2024 TMT & Consumer Conference11 Jan 2026